See more : Silvercorp Metals Inc. (SVM) Income Statement Analysis – Financial Results
Complete financial analysis of BioLineRx Ltd. (BLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLineRx Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chifeng Jilong Gold Mining Co.,Ltd. (600988.SS) Income Statement Analysis – Financial Results
- Bus Online Co., Ltd. (002188.SZ) Income Statement Analysis – Financial Results
- Cleanaway Waste Management Limited (CWY.AX) Income Statement Analysis – Financial Results
- New America Energy Corp. (NECA) Income Statement Analysis – Financial Results
- Ramkrishna Forgings Limited (RKFORGE.BO) Income Statement Analysis – Financial Results
BioLineRx Ltd. (BLRX)
About BioLineRx Ltd.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 113.16M | 113.16M | 63.91M | 31.89M |
| Cost of Revenue | 3.69M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 440.89K | 0.00 | 0.00 | 0.00 | 22.62M | 7.21M |
| Gross Profit | 1.11M | -654.00K | -702.00K | -934.00K | -940.00K | -451.00K | -480.68K | -481.89K | -440.89K | 0.00 | 113.16M | 113.16M | 41.29M | 24.69M |
| Gross Profit Ratio | 23.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 64.60% | 77.40% |
| Research & Development | 12.52M | 17.63M | 19.47M | 18.17M | 23.44M | 19.81M | 19.51M | 11.18M | 11.49M | 10.90M | 12.65M | 17.21M | 11.20M | 15.49M |
| General & Administrative | 16.64M | 5.07M | 4.27M | 3.84M | 3.74M | 4.41M | 4.04M | 3.95M | 3.65M | 3.49M | 3.68M | 3.71M | 3.34M | 4.14M |
| Selling & Marketing | 14.59M | 6.46M | 1.00M | 840.00K | 857.00K | 1.36M | 1.69M | 1.35M | 1.00M | 1.46M | 1.18M | 863.77K | 869.15K | 1.30M |
| SG&A | 31.23M | 11.53M | 5.27M | 4.68M | 4.60M | 5.77M | 5.73M | 5.31M | 4.65M | 4.95M | 4.86M | 4.57M | 4.21M | 5.44M |
| Other Expenses | 7.05M | 5.67M | 42.00K | 70.00K | 78.00K | 27.00K | -260.00K | 7.00K | 153.00K | 2.81M | -280.83K | -322.27K | 0.00 | 50.17K |
| Operating Expenses | 50.80M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 20.98M |
| Cost & Expenses | 54.49M | 29.16M | 24.78M | 22.93M | 28.11M | 25.61M | 25.24M | 16.51M | 16.20M | 15.85M | 17.63M | 21.83M | 15.41M | 28.19M |
| Interest Income | 2.01M | 694.00K | 559.00K | 236.00K | 777.00K | 719.00K | 1.17M | 480.00K | 457.00K | 3.28M | 746.59K | 2.36M | 3.34M | 861.33K |
| Interest Expense | 2.17M | 2.16M | 984.00K | 1.47M | 1.83M | 21.00K | 21.00K | 14.00K | 15.00K | 411.67K | 20.67K | 25.96K | 1.12M | 16.63K |
| Depreciation & Amortization | 1.38M | 654.00K | 702.00K | 934.00K | 940.00K | 451.00K | 480.68K | 481.89K | 441.00K | 246.54K | 329.36K | 407.93K | 410.67K | 511.28K |
| EBITDA | -57.06M | -28.50M | -25.35M | -21.99M | -27.17M | -25.15M | -23.83M | -15.34M | -13.94M | -10.79M | -16.70M | -19.38M | -13.59M | 4.21M |
| EBITDA Ratio | -1,188.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14.88% | -18.90% | -23.47% | 20.90% |
| Operating Income | -49.69M | -29.16M | -24.78M | -22.93M | -28.11M | -25.61M | -25.24M | -16.51M | -16.20M | -15.85M | -17.63M | -21.83M | -15.41M | 3.70M |
| Operating Income Ratio | -1,035.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.58% | -19.29% | -24.11% | 11.61% |
| Total Other Income/Expenses | -10.92M | 4.21M | -2.28M | -7.09M | 2.67M | 2.64M | 888.00K | 672.00K | 1.80M | 6.18M | -13.16K | 1.37M | 1.39M | -1.61M |
| Income Before Tax | -60.61M | -24.95M | -27.05M | -30.02M | -25.45M | -22.96M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | 61.52M | 2.10M |
| Income Before Tax Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | 96.26% | 6.57% |
| Income Tax Expense | 1.00K | -6.08M | 1.09M | 911.00K | 1.36M | -4.46M | -888.00K | -672.00K | -1.80M | -5.68M | 15.79K | -1.42M | -2.22M | 1.61M |
| Net Income | -60.61M | -18.87M | -28.14M | -30.93M | -26.81M | -18.51M | -24.35M | -15.84M | -14.40M | -10.17M | -17.64M | -20.42M | -13.19M | 2.10M |
| Net Income Ratio | -1,262.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -15.59% | -18.04% | -20.63% | 6.57% |
| EPS | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| EPS Diluted | -0.94 | -0.37 | -0.64 | -1.84 | -2.75 | -2.56 | -4.06 | -4.23 | -4.20 | -4.71 | -11.77 | -18.08 | -16.00 | 2.54 |
| Weighted Avg Shares Out | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 823.41K |
| Weighted Avg Shares Out (Dil) | 64.22M | 51.60M | 44.20M | 16.86M | 9.76M | 7.24M | 6.00M | 3.74M | 3.43M | 2.16M | 1.50M | 1.13M | 823.91K | 830.31K |
BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2024 Earnings Call Transcript May 28, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi -...
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
- Steady growth in APHEXDA ® adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients treated 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control ...
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 22, 2024 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel , May 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification...
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- Presentation Today, Monday, May 6, 2024 in Atlanta, Georgia - TEL AVIV, Israel , May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today...
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
TEL AVIV, Israel , April 17, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including...
BioLineRx Announces $6 Million Registered Direct Offering
TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements...
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on formulary approvals at targeted major transplant centers; r eceived Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD, PhD, of...
Source: https://incomestatements.info
Category: Stock Reports